American Journal of Pharmacology and Pharmacotherapeutics

Antibody proteases as a novel biomarker and a unique target to suit translational tools to be applied for bioengineering and biopharma

European Congress on Pharma
August 13-14, 2018 Paris,France

Sergey Suchkov, Noel Rose, Aleks Gabibov and Harry Schroeder

I M Sechenov First Moscow State Medical University, Moscow, Russia A I Evdokimov Moscow State Medical & Dental University, Moscow, Russia EPMA (European Association for Prediction, Prevention and Personalized Medicine), Brus-sels, European Union Johns Hopkins Center for Autoimmune Disease Research, PAHO/WHO Collaborating Cen-ter for Autoimmune Disorders, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA Institute for Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia Division of Immunology & Rheumatology-UAB, Birmingham, Alabama, USA

Posters & Accepted Abstracts: J Pharmacol Pharmacother

DOI: 10.21767/2393-8862-C1-003

Abstract

Catalytic Abs (catAbs) are multivalent im-munoglobulins (Igs) with a capacity to hy-drolyze the antigenic (Ag) substrate. In this sense, proteolytic Abs (Ab-proteases) rep-resent Abs to provide proteolytic effects. Abs against myelin basic protein/MBP with proteolytic activity exhibiting sequence-specific cleavage of MBP is of great value to monitor demyelination whilst in multiple sclerosis (MS). The activity of Ab-proteases was first registered at the subclinical stages 1-2 years prior to the clinical illness. And the activity of the Ab-proteases revealed significant correlation with scales of demy-elination and the disability of the patients as well. So, the activity of Ab-proteases and its dynamics tested would confirm a high subclinical and predictive (translational) value of the tools as applica-ble for personalized monitoring protocols. Of tremendous value are Ab-proteases di-rectly affecting remodeling of tissues with multilevel architectonics (for instance, my-elin). By changing sequence specificity one may reach reduction of a density of the negative proteolytic effects within the mye-lin sheath and thus minimizing scales of demyelination. Ab-proteases can be pro-grammed and re-programmed to suit the needs of the body metabolism or could be designed for the development of new cata-lysts with no natural counterparts. Further studies are needed to secure artificial or edited Ab-proteases as translational tools of the newest generation to diagnose, to moni-tor, to control and to treat and rehabilitate MS patients at clinical stages and to prevent the disorder at subclinical stages in persons-at-risks to secure the efficacy of regenerative manipulations.